Clinically reviewed by Dr. Sarah Boss, MD
New or worsening depression or suicidal thoughts requires prompt assessment. Fever with severe rigidity or confusion, collapse or fainting with palpitations needs urgent care. After more than five days without tetrabenazine, contact the prescriber before restarting. Do not combine it with deutetrabenazine or valbenazine.
Tetrabenazine is a specialist medicine used to reduce certain excessive involuntary movements. Its main US indication is chorea associated with Huntington’s disease; some UK products also have a role in selected persistent tardive dyskinesia. The treatment can affect mood, alertness and movement in other ways, so a good review looks beyond whether the original movements become less visible. It is not a treatment for depression, anxiety or addiction withdrawal.
Huntington’s chorea and country-specific uses
The US prescribing information describes treatment of Huntington’s chorea. Huntington’s disease can involve movement, cognitive and psychiatric changes, and controlling chorea addresses only one part of that picture. Tetrabenazine does not cure the disease or replace wider neurological and mental health care. [1]
Some UK formulations include moderate to severe tardive dyskinesia that persists despite appropriate changes to antipsychotic treatment, or where stopping that treatment is not realistic. Other products have narrower indications. A patient should therefore ask about the actual product and local authorization, rather than assuming that every tetrabenazine tablet has identical licensed uses. [2]
Understanding the movement before treating it
Chorea, tremor, dystonia and akathisia are not interchangeable descriptions. A specialist assessment should establish what is happening and whether medication exposure, a neurological condition or another explanation fits. Bring the timing of symptoms, previous treatments and the activities most affected. A movement that seems minor in the clinic may interfere considerably with eating, writing or conversation.
Agree practical aims with the clinician. Less distress while speaking, easier meals or safer walking may matter more than achieving complete stillness. Conversely, adding marked sedation or stiffness can offset a reduction in chorea. A clear baseline helps make those trade-offs visible during follow-up.
How tetrabenazine changes movement signaling
Tetrabenazine inhibits vesicular monoamine transporter 2, or VMAT2, reducing the storage of neurotransmitters in nerve-cell vesicles. Its effects on dopamine signaling can reduce excessive movement, but can also contribute to unwanted slowing or stiffness. Deutetrabenazine and valbenazine act on the same transporter but are distinct medicines with different prescribing instructions. [3]
The mechanism does not establish that one of these medicines is universally best. The choice depends on the diagnosed syndrome, previous response, other prescriptions and individual vulnerabilities. Do not substitute a related medicine using equal milligrams or leftover supplies from an earlier prescription.
Depression and suicide-risk monitoring
Tetrabenazine carries a boxed warning about depression and suicidality in Huntington’s disease. The US label contraindicates treatment in someone who is actively suicidal or whose depression is untreated or undertreated. Mental health assessment is therefore part of suitability, not simply a warning to read after treatment starts. [1]
Report new hopelessness, loss of interest, unusual irritability, marked anxiety or thoughts of self-harm promptly. Immediate suicidal danger needs emergency assessment. Agree with the team how the patient and, where appropriate, family members will report changes between visits. Do not wait for a routine movement appointment when safety is deteriorating.
Coordinating with psychiatric treatment
When tardive dyskinesia is involved, the clinician responsible for the original psychiatric condition should remain part of the plan. A movement prescription does not remove the need for an antipsychotic or antidepressant review, and it does not justify abrupt stopping. Some combinations can be appropriate under specialist care, but the purpose and monitoring should be explicit.
Ask which symptoms are being targeted by each medicine. A shared list should include regular and occasional prescriptions, as well as recent changes. It is particularly useful when different services might otherwise interpret worsening movement, low mood or sleepiness without knowing what the other team has changed.
Starting treatment and measuring response
Tetrabenazine is individually titrated, with adjustments guided by benefit and adverse effects. Follow the written prescription rather than a generic online schedule. The medicine may be taken with or without food under the US patient information, but instructions for the supplied product should be checked. [3]
Record how the target movements and ordinary activities change, together with mood, alertness and balance. Avoid judging the whole treatment by a single unusually difficult day. Tell the team when the schedule is impractical or swallowing is difficult, so they can address the problem rather than relying on an assumed pattern of use.
Why CYP2D6 may need attention
CYP2D6 is an enzyme involved in handling tetrabenazine’s active metabolites. Under the US label, genotyping is required before prescribing above a specified daily-dose threshold. People who metabolize the medicine slowly and people taking strong CYP2D6 inhibitors have different prescribing limits. The test and dose decision belong with the clinician. [1]
Fluoxetine and paroxetine are important examples of interacting antidepressants. A person should not stop either independently to accommodate a movement medicine. Ask whether the interaction changes the chosen treatment, its amount or the follow-up plan. A previous genetic result should be shared, but does not replace a full medication review.
Other important interactions
MAO inhibitors, reserpine, deutetrabenazine and valbenazine have specific contraindications or transition restrictions. Other medicines that prolong the QT interval can add cardiac risk, while alcohol and sedating treatments can worsen sleepiness. Antipsychotics may add Parkinsonian effects or other dopamine-related adverse effects. [1]
Have combinations checked before starting nonprescription products or accepting a prescription from another service. Tell the pharmacist what was recently stopped as well as what is currently taken. Do not calculate your own waiting interval when switching medicines; it depends on the actual products and the clinical situation.
Common unwanted effects
Sleepiness, fatigue, insomnia, anxiety, restlessness, nausea and other digestive symptoms can occur. Dizziness on standing may increase the risk of a fall. Do not drive or operate hazardous machinery while drowsy or otherwise impaired. Persistent symptoms deserve review even when they do not qualify as an emergency. [3]
Describe the effect on daily life: whether meals take longer, conversations are harder or naps have increased. A caregiver’s observations can complement the patient’s report. Quietness alone should not be interpreted as improvement, particularly when fatigue, depression or reduced engagement could explain the change.
New stiffness, swallowing problems and restlessness
Tetrabenazine can cause Parkinsonian symptoms and akathisia. It can also complicate swallowing in vulnerable people. New rigidity, slowed movement, falls, difficulty swallowing or a persistent need to move warrants prompt assessment. These symptoms may require adjustment rather than adding another medicine without reviewing the cause. [2]
Explain when symptoms appeared in relation to the treatment schedule. A person can have improvement in chorea and worsening stiffness at the same time, which is why assessment must consider more than one movement pattern. Breathing or severe swallowing difficulty should be treated urgently rather than documented for the next routine visit.
Liver health, cardiac precautions and emergencies
Hepatic impairment is a contraindication because drug handling can change substantially. Cardiac rhythm history, low potassium or magnesium and other QT-related medicines need review. Fever with severe rigidity, confusion or unstable circulation can indicate neuroleptic malignant syndrome. Collapse, fainting with palpitations or a seizure also requires urgent care. [1]
Keep an accessible medication list for emergency staff. A new serious symptom should not be dismissed as a predictable part of Huntington’s disease or a psychiatric diagnosis. The priority is assessment, not identifying the responsible medicine at home or waiting for an admissions response.
Stopping, interrupted treatment and return of symptoms
The US prescribing information permits stopping without tapering, but treatment interrupted for more than five days requires re-titration when resumed. Contact the prescriber before restarting after such an interruption. The former maintenance regimen should not be resumed automatically without considering why treatment stopped and whether health or other medication has changed. [1]
Chorea can return after symptomatic treatment is removed. That does not in itself demonstrate addiction withdrawal. A planned discontinuation still needs an observation and support plan, especially when mobility or feeding may be affected. Switching to another VMAT2 inhibitor requires a separate clinician-led transition.
Addiction, detox and alcohol-related questions
Tetrabenazine does not treat alcohol, opioid or benzodiazepine withdrawal. Alcohol can add to sedation and make balance, mood or cognition harder to assess. Using a movement medicine to manage an unexplained shaking episode is unsafe because the cause could be a medical emergency or withdrawal requiring a different approach.
Describe substance use and recent reductions honestly when seeking care. The relevant question is how to coordinate neurological, psychiatric and addiction treatment, not whether one diagnosis cancels another. The integrated medication-planning guide provides a starting point for that conversation.
Pregnancy and practical follow-up
Pregnancy planning, breastfeeding and possible pregnancy should be discussed with the specialist because evidence and individual risks need assessment. Do not extrapolate adult prescribing to a child. Keep appointments for the agreed monitoring and ask who is responsible for reviewing results, renewing prescriptions and handling changes in supply. [3]
Bring the medication-review checklist and a short record of movements, mood, sleepiness and falls. The aim is a treatment decision that remains understandable and workable, not simply continuing the prescription because it was once started.
Frequently asked questions
Is tetrabenazine licensed for every movement disorder?
No. Uses vary by diagnosis, country and product. US and UK labeling should not be treated as identical.
Does it treat the psychiatric cause of tardive dyskinesia?
It may reduce selected involuntary movements, but the original psychiatric condition still requires its own treatment and review.
Can I combine it with another VMAT2 inhibitor?
No independent combination is appropriate. Related medicines have specific contraindications and switching instructions that require the specialist’s plan.
Is depression just a symptom to mention at the next visit?
No. New or worsening depression needs prompt contact; immediate suicidal danger requires emergency assessment.
